Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03070899 is registered in ClinicalTrials.gov with ObsEva SA as lead sponsor.

NCT NCT03070899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03070899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Lead sponsor
ObsEva SA
Phase
Phase 3
Overall status
Completed
Start date
April 20, 2017
Completion date
April 12, 2021
Enrollment
526 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

heavy menstrual bleeding, uterine fibroids